Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I clinical trial of ATG-019 (monotherapy or combined with niacin ER) in patients with advanced solid tumors or non-Hodgkin's lymphoma

Next Previous
X
Search
Trial Profile

Phase I clinical trial of ATG-019 (monotherapy or combined with niacin ER) in patients with advanced solid tumors or non-Hodgkin's lymphoma

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 13 Apr 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Padnarsertib (Primary) ; Niacin
  • Indications Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Antengene Corporation

    • Most Recent Events

    • 13 Apr 2021 According to an ANtengene Corporation media release, the company announced that the National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for this phase I clinical trial in mainland China.
    • 13 Apr 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top